GlassScriptPhysician profile
Gregory A Merritt
NPI 1548266174
$16,470.49
in general payments reported to CMS, 2019-2025
41 companies · $2,891 in 2025
The $2,891 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $67.75 · 2021: $1,580 · 2022: $2,907 · 2023: $4,251 · 2024: $3,574 · 2025: $2,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $45.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,669.72 |
| Education | $45.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,932.00 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,203.30 | 2020-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $1,817.78 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,444.36 | 2020-2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $1,008.51 | 2022-2025 | Sucraid, Sucraid |
| Medtronic Vascular, INC. | $940.03 | 2019 | |
| Ardelyx, INC. | $644.27 | 2022-2025 | Ibsrela |
| Celgene Corporation | $612.81 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $586.34 | 2021-2024 | Dificid, Zinplava |
| Pfizer INC. | $583.18 | 2021-2025 | |
| Lilly USA, LLC | $491.71 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $360.53 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $351.56 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $315.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $298.79 | 2022-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Merritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.